The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival

被引:37
作者
Delitto, Daniel [1 ]
Black, Brian S. [1 ]
Sorenson, Heather L. [2 ]
Knowlton, Andrea E. [2 ]
Thomas, Ryan M. [1 ,3 ]
Sarosi, George A. [1 ,3 ]
Moldawer, Lyle L. [1 ]
Behrns, Kevin E. [1 ]
Liu, Chen [4 ]
George, Thomas J. [5 ]
Trevino, Jose G. [1 ]
Wallet, Shannon M. [2 ]
Hughes, Steven J. [1 ]
机构
[1] Univ Florida, Hlth Sci Ctr, Coll Med, Dept Surg,Shands Hosp, Gainesville, FL 32610 USA
[2] Univ Florida, Hlth Sci Ctr, Coll Dent, Dept Oral Biol, Gainesville, FL 32610 USA
[3] Univ Florida, Coll Med, Dept Surg, North Florida South Georgia Vet Hlth Syst, Gainesville, FL 32610 USA
[4] Univ Florida, Hlth Sci Ctr, Coll Med, Dept Pathol, Gainesville, FL 32610 USA
[5] Univ Florida, Hlth Sci Ctr, Coll Med, Dept Med, Gainesville, FL 32610 USA
来源
BMC CANCER | 2015年 / 15卷
关键词
Inflammation; Cytokines; Chemokines; Growth factors; Pancreatic cancer; Tumor microenvironment; PREOPERATIVE CHEMORADIATION; CARCINOMA-CELLS; STELLATE CELLS; TUMOR STROMA; T-CELLS; GEMCITABINE; THERAPY; ADENOCARCINOMA; BIOMARKERS; CHEMORADIOTHERAPY;
D O I
10.1186/s12885-015-1820-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The tumor microenvironment impacts pancreatic cancer (PC) development, progression and metastasis. How intratumoral inflammatory mediators modulate this biology remains poorly understood. We hypothesized that the inflammatory milieu within the PC microenvironment would correlate with clinicopathologic findings and survival. Methods: Pancreatic specimens from normal pancreas (n = 6), chronic pancreatitis (n = 9) and pancreatic adenocarcinoma (n = 36) were homogenized immediately upon resection. Homogenates were subjected to multiplex analysis of 41 inflammatory mediators. Results: Twenty-three mediators were significantly elevated in adenocarcinoma specimens compared to nonmalignant controls. Increased intratumoral IL-8 concentrations associated with larger tumors (P = .045) and poor differentiation (P = .038); the administration of neoadjuvant chemotherapy associated with reduced IL-8 concentrations (P = .003). Neoadjuvant therapy was also associated with elevated concentrations of Flt-3 L (P = .005). Elevated levels of pro-inflammatory cytokines IL-1 beta (P =.017) and TNF alpha (P = .033) were associated with a poor histopathologic response to neoadjuvant therapy. Elevated concentrations of G-CSF (P = .016) and PDGF-AA (P = .012) correlated with reduced overall survival. Conversely, elevated concentrations of FGF-2 (P = .038), TNF alpha (P = .031) and MIP-1 alpha (P = .036) were associated with prolonged survival. Conclusion: The pancreatic cancer microenvironment harbors a unique inflammatory milieu with potential diagnostic and prognostic value.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] [Anonymous], ENDOSCOPY
  • [2] Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer
    Ansari, D.
    Rosendahl, A.
    Elebro, J.
    Andersson, R.
    [J]. BRITISH JOURNAL OF SURGERY, 2011, 98 (08) : 1041 - 1055
  • [3] Mortality, Cancer, and Comorbidities Associated With Chronic Pancreatitis: A Danish Nationwide Matched-Cohort Study
    Bang, Ulrich Christian
    Benfield, Thomas
    Hyldstrup, Lars
    Bendtsen, Flemming
    Jensen, Jens-Erik Beck
    [J]. GASTROENTEROLOGY, 2014, 146 (04) : 989 - U528
  • [4] CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
    Beatty, Gregory L.
    Chiorean, Elena G.
    Fishman, Matthew P.
    Saboury, Babak
    Teitelbaum, Ursina R.
    Sun, Weijing
    Huhn, Richard D.
    Song, Wenru
    Li, Dongguang
    Sharp, Leslie L.
    Torigian, Drew A.
    O'Dwyer, Peter J.
    Vonderheide, Robert H.
    [J]. SCIENCE, 2011, 331 (6024) : 1612 - 1616
  • [5] Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival
    Bellone, G
    Smirne, C
    Mauri, FA
    Tonel, E
    Carbone, A
    Buffolino, A
    Dughera, L
    Robecchi, A
    Pirisi, M
    Emanuelli, G
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (06) : 684 - 698
  • [6] Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival Duration
    Tara M. Breslin
    Kenneth R. Hess
    Dana B. Harbison
    Marina E. Jean
    Karen R. Cleary
    Alan P. Dackiw
    Robert A. Wolff
    James L. Abbruzzese
    Nora A. Janjan
    Christopher H. Crane
    J. Nicolas Vauthey
    Jeffrey E. Lee
    Peter W. T. Pisters
    Douglas B. Evans
    [J]. Annals of Surgical Oncology, 2001, 8 (2) : 123 - 132
  • [7] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
    Burris, HA
    Moore, MJ
    Andersen, J
    Green, MR
    Rothenberg, ML
    Madiano, MR
    Cripps, MC
    Portenoy, RK
    Storniolo, AM
    Tarassoff, P
    Nelson, R
    Dorr, FA
    Stephens, CD
    VanHoff, DD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) : 2403 - 2413
  • [8] Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma
    Chatterjee, Deyali
    Katz, Matthew H.
    Rashid, Asif
    Estrella, Jeannelyn S.
    Wang, Hua
    Varadhachary, Gauri R.
    Wolff, Robert A.
    Lee, Jeffrey E.
    Pisters, Peter W.
    Abbruzzese, James L.
    Fleming, Jason B.
    Wang, Huamin
    [J]. HISTOPATHOLOGY, 2013, 63 (06) : 841 - 851
  • [9] Tumor Necrosis Factor Induces Tumor Promoting and Anti-Tumoral Effects on Pancreatic Cancer via TNFR1
    Chopra, Martin
    Lang, Isabell
    Salzmann, Steffen
    Pachel, Christina
    Kraus, Sabrina
    Baeuerlein, Carina A.
    Brede, Christian
    Garrote, Ana-Laura Jordan
    Mattenheimer, Katharina
    Ritz, Miriam
    Schwinn, Stefanie
    Graf, Carolin
    Schaefer, Viktoria
    Frantz, Stefan
    Einsele, Hermann
    Wajant, Harald
    Beilhack, Andreas
    [J]. PLOS ONE, 2013, 8 (09):
  • [10] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
    Conroy, Thierry
    Desseigne, Francoise
    Ychou, Marc
    Bouche, Olivier
    Guimbaud, Rosine
    Becouarn, Yves
    Adenis, Antoine
    Raoul, Jean-Luc
    Gourgou-Bourgade, Sophie
    de la Fouchardiere, Christelle
    Bennouna, Jaafar
    Bachet, Jean-Baptiste
    Khemissa-Akouz, Faiza
    Pere-Verge, Denis
    Delbaldo, Catherine
    Assenat, Eric
    Chauffert, Bruno
    Michel, Pierre
    Montoto-Grillot, Christine
    Ducreux, Michel
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) : 1817 - 1825